Rhematoid ArthritisRA: rheumatoidNCT07814989
Wrist Nerve Block as a New Treatment in Patients With Rheumatoid Arthritis
A study testing Wrist local steroid injection in people with Rhematoid Arthritis, run by Sohag University at 1 site in Egypt.
Trial summary
Rheumatoid arthritis is a chronic, systemic, autoimmune inflammatory disease that mainly affects the joints and periarticular soft tissues.[1] Read more about this study
- Who is it for?
- Ages 16 to 60 years
- Conditions the study is for
- Rhematoid Arthritis
- What is being tested?
- Wrist local steroid injection
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 180 participants
- Where
- 1 siteEgypt
- Study dates
- 15 Aug 2026to 1 Jul 2027
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 to 60 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- RA patients fulfilled the 2010 American College of Rheumatoid Arthritis classification criteria.[8]
- Oligoarticular RA patients including wrist joint.
- Age above 18 years old.
- Patient cooperative and can answer questions.
Who cannot join
- Other rheumatologic or collagen diseases.
- Age below 18 years.
- Patients who underwent concomitant procedures to address underlying pathology such as radial styloidectomy, ulna shortening, fracture fixation, arthroplasty, arthrodesis, and ligament reconstructions.
- Patients who suffered from hand deformities or limitation.
- Uncooperative patients.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Ahmed mahrous elsamman contact
About this study
Official title: The Role of Wrist Nerve Block as a Therapeutic Modality in Patients With Rheumatoid Arthritis
Rheumatoid arthritis is a chronic, systemic, autoimmune inflammatory disease that mainly affects the joints and periarticular soft tissues.[1]
- Conditions
- Rhematoid Arthritis
- Being tested
- Wrist local steroid injection
- Keywords
- Rheumatoid Arthritis, Nerve block, Wrist injection
- Medical subject headings
- Arthritis, Rheumatoid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Wrist local steroid injectionProcedure or surgery
Wrist nerve block by injection is a diagnostic or therapeutic procedure used to treat chronic wrist pain, typically arising from arthritis or instability, by interrupting sensory nerve signals (mainly PIN/AIN nerves) with an anesthetic or neurolytic agent. This less-invasive approach provides pain relief, often serving as a predictor for success before permanent surgical denervation.[4]
| Study group | Role | What they receive |
|---|---|---|
| Group 1 | Active comparator | wrist nerve block Receives: Procedure: Wrist local steroid injection |
| Group 2 | Placebo comparator | wrist local steroid injection Receives: Procedure: Wrist local steroid injection |
| Group 3 | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in wrist pain severity measured by the Visual Analogue Scale (VAS) from baseline to Week 16
Change in wrist pain severity measured using the Visual Analogue Scale (VAS) from baseline to Week 16 Visual Analogue Scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain.
Wrist pain severity will be assessed using the Visual Analogue Scale (VAS), ranging from 0 to 10, where 0 represents no pain and 10 represents the worst imaginable pain. Higher scores indicate greater pain. The change in VAS score from baseline to Week 16 will be assessed.
Measured: Baseline to Week 16
Assessment of wrist pain improvement
- Change in wrist pain severity measured by the Visual Analogue Scale (VAS) from baseline to Week 16
Measured: 16 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Sep 2026
- Study start15 Aug 2026 (estimated)
- Primary completion1 Jan 2027 (estimated)
- Study completion1 Jul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Rhematoid ArthritisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 180 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yousra Aly Lamie, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07814989
- Sponsor's protocol ID
- Soh-Med-26-7-26MS
- Acronym
- RA: rheumatoid
- Status last verified
- Jul 2026
- First submitted
- 30 Aug 2026
- Last updated
- 11 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided